Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core

Eur J Med Chem. 2021 Jan 15:210:112959. doi: 10.1016/j.ejmech.2020.112959. Epub 2020 Oct 22.

Abstract

HSP90-CDC37 protein-protein interaction (PPI) works as a kinase specific-molecular chaperone system to regulate the maturation of kinases. Currently, selectively disrupting HSP90-CDC37 PPI, rather than the direct inhibition of the ATPase function of HSP90, is emerging as a promising strategy for cancer therapy by specifically blocking the maturation of kinases. However, due to the limited understanding of HSP90-CDC37 binding interface, design of small molecule inhibitors targeting HSP90-CDC37 PPI is challenging. In this work, based on the binding mode of compound 11 (previously reported by our group), we discovered a hydrophobic pocket centered on Phe213, which was previously unknown, contributing to the binding affinity of HSP90-CDC37 PPI inhibitors. A series of hydrophobic substituted inhibitors were utilized to confirm the importance of Phe213 hydrophobic core. Finally, we obtained an optimum compound DDO-5994 (exhibited an ideal binding pattern on hydrophobic core) with improved binding affinity (KD = 5.52 μM) and antiproliferative activity (IC50 = 6.34 μM). Both in vitro and in vivo assays confirmed DDO-5994 as a promising inhibitor to exhibit ideal antitumor efficacy through blocking HSP90-CDC37 PPI.

Keywords: Anti-proliferation activity; HSP90-CDC37; Kinase maturation; Protein-protein interaction inhibitors.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Cell Cycle Proteins / metabolism*
  • Cell Proliferation / drug effects
  • Chaperonins / metabolism*
  • Drug Design
  • HCT116 Cells
  • HSP90 Heat-Shock Proteins / metabolism*
  • Humans
  • Hydrophobic and Hydrophilic Interactions / drug effects
  • Mice
  • Models, Molecular
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Protein Interaction Maps / drug effects*

Substances

  • Antineoplastic Agents
  • CDC37 protein, human
  • Cell Cycle Proteins
  • HSP90 Heat-Shock Proteins
  • Chaperonins